NVS logo

NVS
Novartis AG

6,820
Mkt Cap
$275.36B
Volume
2.03M
52W High
$146.35
52W Low
$97.72
PE Ratio
19.65
NVS Fundamentals
Price
$145.11
Prev Close
$143.58
Open
$143.82
50D MA
$134.97
Beta
0.25
Avg. Volume
1.52M
EPS (Annual)
$5.91
P/B
6.28
Rev/Employee
$662,711.55
Loading...
Loading...
News
all
press releases
Roche's Genentech Expands Investment in North Carolina Facility to $2B
Roche more than doubles Genentech's Holly Springs biomanufacturing investment to approximately $2B, boosting U.S. supply-chain resilience and metabolic drug production.
Zacks·10h ago
News Placeholder
More News
News Placeholder
Dynasty Wealth Management LLC Makes New $1.49 Million Investment in Novartis AG $NVS
Dynasty Wealth Management LLC purchased a new position in shares of Novartis AG (NYSE:NVS - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and...
MarketBeat·17h ago
News Placeholder
Trump Doing 'Permanent Damage' To US, Says Bremmer in Davos The Pulse 1/20
President Trump says he will hold talks over Greenland, after threatening new tariffs on European countries getting in his way. France has pushed back most forcefully, and now Donald Trump has...
Bloomberg Markets and Finance-YouTube·2d ago
News Placeholder
Novartis could have a U.S. deal that shields it from tariffs, CEO tells CNBC
The continent's pharma sector could be one of its worst hit by Trump's latest tariffs on some European countries...
CNBC: World News·2d ago
News Placeholder
Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease
FDA grants Breakthrough Therapy status to NVS's ianalumab for Sjogren's disease with plans for global filings starting in 2026.
Zacks·2d ago
News Placeholder
Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan
Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.
Zacks·3d ago
News Placeholder
Zacks Research Has Bearish Forecast for Novartis Q1 Earnings
Novartis AG (NYSE:NVS - Free Report) - Research analysts at Zacks Research reduced their Q1 2027 earnings per share estimates for Novartis in a report released on Friday, January 16th. Zacks Research...
MarketBeat·3d ago
News Placeholder
QRG Capital Management Inc. Has $16.10 Million Position in Novartis AG $NVS
QRG Capital Management Inc. decreased its position in shares of Novartis AG (NYSE:NVS - Free Report) by 34.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities...
MarketBeat·5d ago
News Placeholder
Novartis AG $NVS Stake Increased by Csenge Advisory Group
Csenge Advisory Group boosted its stake in Novartis AG (NYSE:NVS - Free Report) by 58.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange...
MarketBeat·5d ago
News Placeholder
Novartis (NYSE:NVS) Raised to Buy at Wall Street Zen
Wall Street Zen raised Novartis from a "hold" rating to a "buy" rating in a report on Saturday...
MarketBeat·5d ago
<
1
2
...
>

Latest NVS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.